Skip to main content

Pfizer, Inc. (PFE) Stock

Pfizer, Inc. Stock Details, Movements and Public Alerts

Pfizer Inc (PFE): The Post-Covid Pharma Giant Rebuilding Around Oncology and Obesity

The Covid windfall is fading, and Pfizer's next act depends on whether Albert Bourla can transform $43 billion worth of acquisitions into durable growth franchises. The Seagen deal brought a leading antibody-drug conjugate platform. The Metsera partnership targets the obesity market with monthly GLP-1 injections that could differentiate against Novo Nordisk's Ozempic and Eli Lilly's Mounjaro. Pfizer's non-Covid revenue grew 6% operationally in 2025, with $10 billion in annual sales from new products growing at double-digit rates. But the math is unforgiving: Covid product revenues will drop another $1.5 billion in 2026, and several legacy drugs face patent cliffs. Trading around $27 with a 6%+ dividend yield, Pfizer offers income investors a pharma heavyweight at a discount, provided the pipeline delivers.

52-Week Range

$27.94 - $20.92

-4.44% from high · +27.63% from low

Avg Daily Volume

37,413,243

20-day average

100-day avg: 57,032,760

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

19.57

Near market average

Forward P/E

9.40

Earnings expected to grow

Price to Book

1.75

EV/EBITDA

8.00

EPS (TTM)

$1.36

Price to Sales

2.42

Beta

0.41

Less volatile than market

Q:How is PFE valued relative to its earnings and growth?
Pfizer, Inc. trades at a P/E ratio of 19.57, which is near the market average of approximately 20, suggesting the market views it as fairly valued relative to its earnings. Looking ahead, the forward P/E of 9.40 is lower than the current P/E, indicating analysts expect earnings to grow over the next year.
Q:What is PFE's risk profile compared to the market?
With a beta of 0.41, Pfizer, Inc. is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 1.75 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

12.42%

Operating Margin

23.95%

EBITDA

$25.72B

Return on Equity

8.89%

Return on Assets

5.68%

Revenue Growth (YoY)

-1.20%

Q:How profitable and efficient is PFE's business model?
Pfizer, Inc. achieves a profit margin of 12.42%, meaning it retains $12.42 from every $100 in revenue after all expenses. This represents a solid margin typical of well-run businesses, showing the company can effectively balance revenue generation with cost control. The operating margin of 23.95% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 8.89% and ROA at 5.68%, the company achieves moderate returns on invested capital.
Q:What are PFE's recent growth trends?
Pfizer, Inc.'s revenue declined by 1.20% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions. These growth metrics should be evaluated against Drug Manufacturers - General industry averages for proper context.

Dividend Information

Dividend Per Share

$1.72

Dividend Yield

6.46%

Ex-Dividend Date

Jan 23, 2026

Dividend Date

Mar 6, 2026

Q:What dividend income can investors expect from PFE?
Pfizer, Inc. offers a dividend yield of 6.46%, paying $1.72 per share annually. This high yield exceeds 4%, significantly outperforming the S&P 500 average of 1.5-2% and most investment-grade bonds. For income-focused investors, this represents an attractive cash flow opportunity, though high yields sometimes signal market concerns about sustainability. To receive the next dividend, shares must be purchased before the ex-dividend date of Jan 23, 2026.
Q:How reliable is PFE's dividend for long-term investors?
The dividend sustainability can be assessed through the payout ratio - Pfizer, Inc. pays $1.72 per share in dividends against earnings of $1.36 per share, resulting in a payout ratio of 100.00%. This very high payout exceeding 90% raises sustainability concerns, as nearly all earnings go to dividends. Any earnings decline could force a dividend cut. The next dividend payment is scheduled for Mar 6, 2026.

Company Size & Market

Market Cap

$151.3B

Revenue (TTM)

$62.58B

Revenue/Share (TTM)

$11.01

Shares Outstanding

5.69B

Book Value/Share

$15.21

Asset Type

EQUITY

Q:What is PFE's market capitalization and position?
Pfizer, Inc. has a market capitalization of $151.3B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 5.69B shares outstanding, the company's ownership is widely distributed. As a major player in the Drug Manufacturers - General industry, it competes with other firms in this sector.
Q:How does PFE's price compare to its book value?
Pfizer, Inc.'s book value per share is $15.21, while the current stock price is $26.70, resulting in a price-to-book (P/B) ratio of 1.76. This reasonable premium to book value suggests the market values the company's earnings power and intangible assets appropriately. Most profitable companies trade between 1-3x book value. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$28.43

6.46% upside potential

Analyst Recommendations

Strong Buy

2

Buy

7

Hold

16

Sell

1

Strong Sell

2

Q:How reliable are analyst predictions for PFE?
28 analysts cover PFE with 32% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $28.43 implies 6.5% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on PFE?
Current analyst recommendations:2 Strong Buy, 7 Buy, 16 Hold, 1 Sell, 2 Strong Sell. The neutral stance suggests uncertainty or fair valuation at current levels.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Mar 17, 2026, 02:03 AM

Technical Indicators

RSI (14-day)

47.41

Neutral

50-Day Moving Average

$26.35

1.33% above MA-50

200-Day Moving Average

$24.57

8.67% above MA-200

MACD Line

0.07

MACD Signal

0.17

MACD Histogram

-0.10

Bearish

Q:What does PFE's RSI value tell investors?
The RSI (Relative Strength Index) for PFE is currently 47.41, indicating the stock is in neutral territory (40-60 range). Neither buyers nor sellers have clear control, suggesting consolidation or balanced market forces. Combined with the price being above the 50-day moving average, this shows mixed signals requiring careful analysis.
Q:How should traders interpret PFE's MACD and moving average crossovers?
MACD analysis shows the MACD line at 0.07 below the signal line at 0.17, with histogram at -0.10. This bearish crossover indicates downward pressure. The 50-day MA ($26.35) is above the 200-day MA ($24.57), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently above both MAs, confirming strength.

Indicators last updated: Mar 17, 2026, 01:02 AM

Active Alerts

Alert Condition
Price decreases by
Threshold
7%
Created
Feb 12, 2026, 03:59 PM
Alert Condition
Forward P/E falls below
Threshold
7.37 x
Created
Jan 21, 2026, 05:21 PM
Alert Condition
MA Breakout (Bearish)
Threshold
50 days
Created
Jan 20, 2026, 05:18 PM
Alert Condition
Price rises above
Threshold
$27.50
Created
Nov 13, 2025, 03:24 PM
Alert Condition
Price rises above
Threshold
$29.00
Created
Sep 6, 2025, 08:46 AM

Pfizer Inc (PFE) Stock Analysis 2025: Complete Investment Guide

Life After Covid

Pfizer's Covid franchise generated over $100 billion in cumulative revenue from Comirnaty vaccines and Paxlovid antiviral treatments. That chapter is closing. Covid product sales will drop another $1.5 billion in 2026, and the company needs its acquisition-fueled pipeline to fill the gap. CEO Albert Bourla has spent aggressively to get there, most notably the $43 billion Seagen acquisition in late 2023 that made Pfizer a major oncology player overnight.

Bourla described 2025 as a year of strong execution where Pfizer over-delivered on financial commitments. The non-Covid business grew 6% operationally, and $10 billion in revenue now comes from recently launched or acquired products growing at double-digit rates. The question for investors: is that growth sufficient to offset the structural revenue decline from Covid and approaching patent expirations?

Business Model and Competitive Position

Pfizer is a diversified pharmaceutical company with strength across oncology, immunology, rare disease, and vaccines. The Seagen deal added a leading antibody-drug conjugate (ADC) technology platform, including Padcev (bladder cancer) and Adcetris (lymphoma). Legacy franchises include Eliquis (blood thinner, co-marketed with BMS), Ibrance (breast cancer), Prevnar vaccines, and Vyndaqel (cardiac disease).

Competitive advantages include global commercial scale across 185+ countries, one of the industry's largest R&D budgets, and manufacturing infrastructure built during the Covid vaccine rollout. The Seagen acquisition added differentiated biology in ADCs that competitors are racing to replicate. Pfizer now holds multiple vedotin-based conjugates targeting IB6 and PD-L1 alongside CDK4 inhibitor PF-07220060 for breast cancer.

Financial Performance

  • •Revenue: $62.6B FY2025, down 2% YoY (but non-Covid portfolio up 6% operationally)
  • •2026 Guidance: $59.5B-$62.5B, reflecting $1.5B Covid decline + $1.5B patent expiration impact
  • •New Product Revenue: $10B+ annually from recent launches/acquisitions, growing at double-digit rates
  • •Shareholder Returns: $9.8B returned in 2025 via dividends; 6%+ current yield
  • •Cost Savings: Multi-billion dollar restructuring program to offset revenue headwinds
  • •BD Capacity: ~$6B annual capacity for additional business development deals

Growth Catalysts

  • •Obesity Pipeline: Metsera launching up to 10 Phase III trials in 2026 for monthly GLP-1 and amylin therapies; early data shows 10-12% placebo-adjusted weight loss with projected 16% at higher doses
  • •Oncology Expansion: Seagen ADC platform with multiple late-stage programs; CDK4 inhibitor targeting Ibrance's successor market
  • •Vyndaqel Growth: Cardiac amyloidosis treatment expanding into earlier-stage patients with significant market opportunity
  • •Pipeline Depth: 100+ programs with significant Phase III starts planned across oncology, obesity, and immunology
  • •RSV and Vaccines: Abrysvo RSV vaccine for older adults and maternal immunization expanding globally

Risks and Challenges

  • •Covid Revenue Decline: Comirnaty and Paxlovid sales continuing to erode, creating a multi-billion dollar headwind through 2027
  • •Patent Cliffs: Eliquis (co-marketed with BMS) faces biosimilar competition starting 2026-2028, a $5B+ annual revenue risk
  • •Obesity Competition: Novo Nordisk (Ozempic/Wegovy) and Eli Lilly (Mounjaro/Zepbound) hold years-long head starts in GLP-1 market
  • •Seagen Integration: $43B acquisition must deliver returns; $4.4B in impairment charges already taken on underperforming pipeline assets
  • •Debt Load: Seagen acquisition added significant leverage; deleveraging constrains flexibility for additional large deals

Competitive Landscape

In oncology, Pfizer competes against Merck (Keytruda franchise), Roche, AstraZeneca, and Bristol-Myers Squibb. The ADC space is increasingly crowded, with Daiichi Sankyo/AstraZeneca's Enhertu and multiple competitors developing next-generation conjugates. In obesity, Pfizer is a late entrant against Novo Nordisk and Eli Lilly, though monthly dosing could differentiate against their weekly injection schedules.

Among diversified pharma peers, Pfizer trades at a notable discount on forward P/E. Johnson & Johnson, Merck, and AbbVie all command premium multiples due to cleaner growth profiles. Pfizer's discount reflects investor skepticism about the Covid-to-pipeline transition and the Seagen deal's return on investment.

Who Is This Stock Suitable For?

Perfect For

  • ✓Income investors seeking 6%+ dividend yield from a large-cap pharma company
  • ✓Value investors comfortable buying during a transition period at a sector discount
  • ✓Long-term holders (3-5 years) willing to wait for pipeline catalysts to materialize
  • ✓Diversified portfolio builders wanting pharmaceutical sector exposure

Less Suitable For

  • ✗Growth investors needing near-term revenue acceleration
  • ✗Investors uncomfortable with pipeline binary outcomes (obesity trials, oncology approvals)
  • ✗Those seeking capital appreciation over income (stock has underperformed for 3 years)
  • ✗Risk-averse investors concerned about $43B acquisition debt and integration execution

Investment Thesis

Pfizer at $27 is a bet that Albert Bourla's acquisition-led strategy will generate enough growth to offset declining Covid revenues and patent expirations. The 6%+ dividend yield provides downside protection and income while investors wait for pipeline readouts. The obesity entry through Metsera could be transformative if monthly dosing proves competitive, though Pfizer is years behind the market leaders.

The upside case requires successful execution across multiple fronts simultaneously: Seagen oncology products hitting commercial targets, obesity trials generating competitive data, and cost restructuring delivering margin improvement. That is a lot to ask, but Pfizer's scale, commercial infrastructure, and R&D budget give it resources that few competitors can match. At current valuations, much of the risk appears priced in.

Conclusion

Pfizer offers an attractive risk-reward for income-focused investors at current valuations. The dividend yield provides a meaningful return floor while multiple pipeline catalysts could drive re-rating over 2026-2027. This is not a momentum stock, but a value and income play with optionality on the obesity and oncology pipelines.
Bull Case
$38 (39% upside) - Obesity data impresses, Seagen delivers, non-Covid growth accelerates
Base Case
$30 (10% upside) - Pipeline progresses steadily, dividend maintained, gradual re-rating
Bear Case
$20 (27% downside) - Obesity trials disappoint, patent cliffs hit harder than expected, dividend at risk

Stay Ahead of the Market with Pfizer, Inc. Alerts

Set up price alerts for Pfizer, Inc. and get notified instantly when the price hits your target. Never miss an important price movement again.